Comparative Pharmacology
Head-to-head clinical analysis: EVZIO versus NALOXONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVZIO versus NALOXONE HYDROCHLORIDE.
EVZIO vs NALOXONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
2 mg intramuscular (IM) or subcutaneous (SC) autoinjector into anterolateral thigh; repeat every 2-3 minutes as needed for opioid overdose.
0.4 mg to 2 mg intravenous, intramuscular, or subcutaneous every 2 to 3 minutes as needed for opioid reversal; may repeat until response achieved. For continuous infusion, 0.25-6.25 mg/hour IV.
None Documented
None Documented
The terminal elimination half-life of naloxone in adults is approximately 1-2 hours. In neonates, half-life may be prolonged to 3-4 hours. Clinical context: Short half-life necessitates repeated dosing or continuous infusion for sustained opioid reversal, especially with long-acting opioids.
Terminal elimination half-life is 1–1.5 hours in adults; shorter in neonates (approx. 3 hours due to immature clearance). Clinically, rapid decline limits duration of antagonism.
Naloxone undergoes extensive hepatic metabolism primarily via glucuronidation, with approximately 70% excreted in urine as naloxone-3-glucuronide. About 25% is excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Primarily hepatic metabolism (glucuronidation) with renal excretion of metabolites. ~70% as naloxone-3-glucuronide in urine, <5% unchanged. Minor fecal elimination (<10%).
Category C
Category A/B
Opioid Antagonist
Opioid Antagonist